Potential Mortality Reduction With Optimal Usage of Sacubitril/Valsartan Therapy for the Treatment of Heart Failure in Costa Rica

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.1386
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Potential Mortality Reduction With Optimal Usage of Sacubitril/Valsartan Therapy for the Treatment of Heart Failure in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Pcv105 - Potential Reduction in Mortality and Hospitalisations With Optimal Usage of Sacubitril/Valsartan Therapy for the Treatment of Heart Failure With Reduced Ejection Fraction in Ireland

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Reply: Sacubitril/Valsartan for Chagas' Heart Disease Heart Failure?

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Cost-Effectiveness of Sacubitril/Valsartan in the Treatment of Heart Failure in Colombia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

The Reverse Remodeling Response to Sacubitril/Valsartan Therapy in Heart Failure With Reduced Ejection Fraction

Cardiovascular Therapeutics
MedicineCardiovascular MedicinePharmacologyCardiology
2018English

Sacubitril-Valsartan in Heart Failure and Multimorbidity Patients

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Profile of Sacubitril/Valsartan in the Treatment of Heart Failure: Patient Selection and Perspectives

Vascular Health and Risk Management
2017English

Perceived Barriers to Sacubitril/Valsartan Use in Patients With Heart Failure

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Pcv82 - Cost-Effectiveness of Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction in Singapore

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy